THU0462 Long term follow-up results of takayasu arteritis cohort: a tertiary-single centre study

Objectives To assess the clinical characteristics and long term follow-up outcomes of patients with Takayasu’s arteritis (TAK) in a tertiary referral centre. Methods In this retrospective study, 107 (F/M: 96/11) patients fullfilling ACR 1990 criteria for Takayasu Arteritis and referred to our centre between 2004 and 2017 were investigated. All clinical and demographic data during first diagnosis and longitudinal follow-up were abstracted from medical records. Relapse was defined according to the physician’s global assessment (PGA). Results The median age was 3014–67 years at symptom onset and 3314–68 years at diagnosis. Median follow-up duration was 72 (6–264) months. According to Hata Angiographic Classification, Type 5 (51.8%) and Type 1 (38.8%) were the most common patterns with the most frequently affected vessel subclavian artery (82.2%). At diagnosis 0.5–1 mg/kg/day corticosteroid treatment was started in 94.6% patients and a steroid-sparing immunsuppressive (IS) agent in 96.3% of the patients. An initial pulse steroid (1 g/day) therapy was chosen for 8 patients. Before diagnosis 24% patients had a history of a revascularisation procedure. After IS treatments, 24% of the patients were undergone a new revascularisation procedure. During follow-up, biologic agents were chosen for 13.8% of the patients (5 infliximab and certolizumab each, 2 adalimumab and 2 tociluzumab). Remission was observed in 84% of the patients. At least one relapse was occured in 43% and >1 relapse in%14 patients. At the last visit 26% were determined to have an active disease. A>4 mg of methylprednisolone dose was required in only 8.4%. Mortality rate was 3.7% (4 patients). Table 1 Clinical characteristics and outcomes of patients Conclusions We have defined the long-term follow-up results of our Takayasu’s arteritis cohort. Comparing with European and Asia series published recently, requirement for a surgical intervention was lower under immunosuppressive treatments in our series. However, disease activity and relapse rate were still high under conventional ISs, suggesting a need for better therapeutic options. Disclosure of Interest None declared